American Journal of Clinical Dermatology

, Volume 6, Issue 2, pp 65–77

Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Childhood Atopic Dermatitis

Leading Article

Abstract

Approximately 10–20% of infants in industrialized countries experience atopic dermatitis. In recent decades topical corticosteroids have been the first-choice therapy for treatment of flares. However, this form of therapy may induce skin atrophy, especially after application to facial lesions or with long-term use. Thus, development of new anti-inflammatory topical agents for the treatment of childhood atopic dermatitis was needed. The topical calcineurin inhibitors tacrolimus and pimecrolimus have an effect on various cells of the cutaneous immune system, specifically on T cells, by inhibiting the phosphatase calcineurin and preventing the transcription of proinflammatory cytokines. In several clinical studies of children and adults with atopic dermatitis, topical calcineurin inhibitors were found to be effective both on the face and the trunk and extremities, in both short- and long-term treatment regimens. Tachyphylaxis or rebound were not observed. In most patients an improvement of their eczema occurred during the first week of treatment, as measured by subjective and objective clinical signs of atopic dermatitis. Treatment significantly reduced the incidence of flares and the need for corticosteroids in children and adults. Treatment success, commonly defined as ‘excellent improvement’ or ‘clearing of all lesions’, was observed in more than one-third of all children treated with 0.03% or 0.1% tacrolimus or 1% pimecrolimus. Topical application of pimecrolimus and tacrolimus does not lead to significant blood concentrations of these agents in the majority of children with atopic dermatitis, and any increase in blood concentrations decreases after a few days of therapy. No changes in laboratory parameters were observed in short- and long-term studies in patients with atopic dermatitis. The most common adverse effect following the application of topical calcineurin inhibitors is mild to moderate symptoms of irritation such as burning, erythema and pruritus, which occurred in up to 20% of all children treated with tacrolimus and 10% of children treated with pimecrolimus, and usually faded after a few days. In contrast to topical corticosteroids, calcineurin inhibitors do not induce skin atrophy, even after long-term use. Topical calcineurin inhibitors have been proven to be effective and have a good safety profile during short-term and long-term use for up to 1 year with pimecrolimus and up to 4 years with tacrolimus. Given the lack of extensive experience with use of topical calcineurin inhibitors over longer periods, regular use of these agents, particularly in children, should be undertaken only after careful consideration of individual cases. Sun protection should also be advised.

References

  1. 1.
    Kapp A. Atopic dermatitis: the skin manifestation of atopy. Clin Exp Allergy. 1995; 25: 210–9PubMedCrossRefGoogle Scholar
  2. 2.
    Schultz Larsen F, Thomas T, Svensson A. The occurrence of atopic dermatitis in North Europe: an international questionnaire study. J Am Acad Dermatol. 1996; 34: 760–4PubMedCrossRefGoogle Scholar
  3. 3.
    Williams HC. Is the prevalence of atopic dermatitis increasing?. Clin Exp Dermatol. 1992; 17: 385–91PubMedCrossRefGoogle Scholar
  4. 4.
    Rajka G. Essential aspects of atopic dermatitis. Berlin: Springer Verlag, 1989CrossRefGoogle Scholar
  5. 5.
    Kemp AS. Cost of illness of atopic dermatitis in children: a social perspective. Pharmacoeconomics. 2003; 21 (2): 105–13PubMedCrossRefGoogle Scholar
  6. 6.
    Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children?. Br J Dermatol. 2001; 143: 514–22CrossRefGoogle Scholar
  7. 7.
    Breuer K, Wulf A, Heratizadeh A, et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy. 2004; 34: 817–24PubMedCrossRefGoogle Scholar
  8. 8.
    Werfel T, Kapp A. Environmental and other major provocation factors in atopic dermatitis. Allergy. 1998; 53: 731–9PubMedCrossRefGoogle Scholar
  9. 9.
    Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. Atopy Patch Test Study Group. J Am Acad Dermatol. 1999; 40: 187–93PubMedCrossRefGoogle Scholar
  10. 10.
    Gondo A, Saeki NTY. Challenge reactions in atopic dermatitis after percutaneous entry of mite allergen. Br J Dermatol. 1986; 115: 485–93PubMedCrossRefGoogle Scholar
  11. 11.
    Wistokat-Wuelfing A, Schmidt P, Darsow U, et al. Atopy patch test reactions are associated with T lymphocyte-mediated allergen-specific immune responses in atopic dermatitis. Clin Exp Allergy. 1999; 29: 513–21CrossRefGoogle Scholar
  12. 12.
    Bruijnzeel PL, Kuijper PH, Kapp A, et al. The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitis. Clin Exp Allergy. 1993; 23: 97–109PubMedCrossRefGoogle Scholar
  13. 13.
    Tanaka Y, Anan S, Yoshida H. Immunohistochemical studies in mite-induced patch test site in atopic dermatitis. J Dermatol Sci. 1990; 1: 361–8PubMedCrossRefGoogle Scholar
  14. 14.
    Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (FcεRI). J Exp Med. 1992; 175: 1285–90PubMedCrossRefGoogle Scholar
  15. 15.
    Mudde GC, von Reijsen FC, Boland GJ, et al. Allergen presentation by epidermal Langerhans cells from patients with atopic dermatitis is mediated by IgE. Immunology. 1990; 69: 335–41PubMedGoogle Scholar
  16. 16.
    Grewe M, Gyufko K, Schlipf E, et al. Lesional expression of interferon-g in atopic eczema. Lancet. 1994; 343: 25–6PubMedCrossRefGoogle Scholar
  17. 17.
    Thepen T, Langeveld-Wiltschut EG, van Reijsen FC, et al. Bi-phasic response against aeroallergen in atopic dermatitis showing a switch from initial TH2 response into a THI response in situ. J Allergy Clin Immunol. 1996; 97: 828–37PubMedCrossRefGoogle Scholar
  18. 18.
    David TJ, Cambridge GC. Bacterial infection and atopic eczema. Arch Dis Child. 1986; 81: 20–3CrossRefGoogle Scholar
  19. 19.
    Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy. 2001; 56: 1034–41PubMedCrossRefGoogle Scholar
  20. 20.
    Hill CJ, Rosenberg A. Adverse effects from topical corticosteroids. Cutis. 1978; 21: 624–48PubMedGoogle Scholar
  21. 21.
    Samat JH. Systemic side-effects of topical preparation in children. Sem Hop. 1982; 58: 1643–9Google Scholar
  22. 22.
    Feiwel M, Kelly WF. Adrenal unresponsiveness associated with clobetasol propionate. Lancet. 1974; II: 112–3CrossRefGoogle Scholar
  23. 23.
    Goto T, Kino T, Hatanaka H. FK506: historical perspectives. Transplant Proc. 1991; 23: 2713–7PubMedGoogle Scholar
  24. 24.
    Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs. 2000; 9: 69–77CrossRefGoogle Scholar
  25. 25.
    Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity. 2000; 12: 359–72PubMedCrossRefGoogle Scholar
  26. 26.
    Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999; 141: 264–73PubMedCrossRefGoogle Scholar
  27. 27.
    Liu J, Farmer JD, Lane WS, et al. Calcineurin is a common target of cyclophilincyclosporine A and FKBP-FK506 complexes. Cell. 1991; 66: 807–15PubMedCrossRefGoogle Scholar
  28. 28.
    Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today. 1992; 13: 136–42PubMedCrossRefGoogle Scholar
  29. 29.
    Mori A, Suko M, Nishizaki Y, et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporine A and glucocorticoid. Int Arch Allergy Immunol. 1994; 104 Suppl. 1: 32–5PubMedCrossRefGoogle Scholar
  30. 30.
    de Paulis A, Cirillo R, Ciccarelli A, et al. Characterization of the anti-inflammatory effect of FK506 on human mast cells. J Immunol. 1991; 147: 4278–85PubMedGoogle Scholar
  31. 31.
    de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol. 1992; 99: 723–8PubMedCrossRefGoogle Scholar
  32. 32.
    Zuberbier T, Chong SU, Grunow K, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 2001; 108: 275–80PubMedCrossRefGoogle Scholar
  33. 33.
    Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506 leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 2001; 107: 519–25PubMedCrossRefGoogle Scholar
  34. 34.
    Panhans-Groß A, Novak N, Kraft S, et al. Human epidermal Langerhans’ cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol. 2001; 107: 345–52PubMedCrossRefGoogle Scholar
  35. 35.
    Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of munine epidermal Langerhans cells. J Invest Dermatol. 2004; 122 (3): 673–84PubMedCrossRefGoogle Scholar
  36. 36.
    Meingassner JG, Kowalski E, Schwendinger H, et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol. 2003; 149 (4): 853–7PubMedCrossRefGoogle Scholar
  37. 37.
    Kino T, Hatanaka H, Hashimoto M. FK506 a novel immunosuppressant isolated from a Streptomyces I: fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40: 1249–55CrossRefGoogle Scholar
  38. 38.
    Pournaras CC, Ldbbe J, Samat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506). J Invest Dermatol. 2001; 116: 480–1PubMedCrossRefGoogle Scholar
  39. 39.
    Remitz A, Kyllönen H, Granlund H, et al. Tacrolimus ointment reduces the staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001; 107: 196–7PubMedCrossRefGoogle Scholar
  40. 40.
    Hank PJ, Leung DYM. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?. J Allergy Clin Immunol. 2001; 107: 391–2CrossRefGoogle Scholar
  41. 41.
    Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992; 27: 29–34PubMedCrossRefGoogle Scholar
  42. 42.
    Petering H, Kiehl P, Breuer K, et al. Pyodernsa gangraenosum: successful topical therapy with tacrolimus (FK506). Hautarzt. 2001; 52: 47–50PubMedCrossRefGoogle Scholar
  43. 43.
    Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first nonsteroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 2000; 42: 349–50PubMedCrossRefGoogle Scholar
  44. 44.
    Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK506) and momethasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol. 2002; 46: 73–7PubMedCrossRefGoogle Scholar
  45. 45.
    Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus. Fur J Dermalot. 2002; 12: 50–2Google Scholar
  46. 46.
    Mrowietz U, Graeber M, Bräutigam M, et al. The novel ascomycin derivate SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol. 1998; 139: 992–6PubMedCrossRefGoogle Scholar
  47. 47.
    Kaliakatsou F, Hodgson TA, Lewsey JD, et al. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol. 2002; 46: 35–41PubMedCrossRefGoogle Scholar
  48. 48.
    Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002; 47: 789–91PubMedCrossRefGoogle Scholar
  49. 49.
    Katoh N, Miham H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol. 2002; 147: 154–6PubMedCrossRefGoogle Scholar
  50. 50.
    Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease. Arch Dermatol. 2001; 137: 1202–6PubMedGoogle Scholar
  51. 51.
    Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J. 2003; 9: 13PubMedGoogle Scholar
  52. 52.
    Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003; 49: 145–7PubMedCrossRefGoogle Scholar
  53. 53.
    Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg. 2001; 20: 233–41PubMedCrossRefGoogle Scholar
  54. 54.
    Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001; 144: 781–7PubMedCrossRefGoogle Scholar
  55. 55.
    Van Leent EJM, Ebelin ME, Burtin PDB, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology. 2002; 204: 63–8PubMedCrossRefGoogle Scholar
  56. 56.
    Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002; 110: 277–84PubMedCrossRefGoogle Scholar
  57. 57.
    Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110: 1–8CrossRefGoogle Scholar
  58. 58.
    Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 2002; 119: 876–87PubMedCrossRefGoogle Scholar
  59. 59.
    Boguniewicz M, Fiedler VC, Rainier S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998; 102: 637–44PubMedCrossRefGoogle Scholar
  60. 60.
    Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001; 44: S47–57PubMedCrossRefGoogle Scholar
  61. 61.
    Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002; 109: 539–46PubMedCrossRefGoogle Scholar
  62. 62.
    Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I efficacy. J Am Acad Dermatol. 2001; 44 Suppl. 1: S28–38PubMedCrossRefGoogle Scholar
  63. 63.
    Ruzicka T, Bieber T, Schoepf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997; 337: 816–21PubMedCrossRefGoogle Scholar
  64. 64.
    Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002; 109: 547–55PubMedCrossRefGoogle Scholar
  65. 65.
    Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol. 1998; 38: 69–76PubMedCrossRefGoogle Scholar
  66. 66.
    Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000; 59: 323–89PubMedCrossRefGoogle Scholar
  67. 67.
    Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentration and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996; 62: 920–5PubMedCrossRefGoogle Scholar
  68. 68.
    McKee M, Segev D, Wise B. Initial experience with FK506 in pediatric renal transplant recipients. J Pediatr Surg. 1997; 32: 688–90PubMedCrossRefGoogle Scholar
  69. 69.
    Younes BS, McDiarmid SV, Martin MG. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation. 2000; 70: 94–9PubMedGoogle Scholar
  70. 70.
    Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001; 137: 747–50PubMedGoogle Scholar
  71. 71.
    Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome. Arch Dermatol. 1999; 135: 823–32PubMedCrossRefGoogle Scholar
  72. 72.
    Boralevi F, Buzenet C, Taieb A. Topical treatment of Netherton’s syndrome with tacrolimus ointment without significant systemic absorption. Br J Dermatol. 2003; 149: 193–227CrossRefGoogle Scholar
  73. 73.
    Aoyama H, Tabata N, Tanaka M, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1 % FK506 ointment. Br J Dermatol. 1995; 133: 492–500CrossRefGoogle Scholar
  74. 74.
    Nakagawa H, Etch T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis [letter]. Lancet. 1994; 344 (8926: 883PubMedCrossRefGoogle Scholar
  75. 75.
    Kang S, Lucky A, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001; 44: S58–64PubMedCrossRefGoogle Scholar
  76. 76.
    Schiffner R, Schiffner-Rohe J, Landthaler M, et al. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics. 2003; 21 (3): 159–79PubMedCrossRefGoogle Scholar
  77. 77.
    Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life in adults and pediatric patients with atopic dermatitis. J Am Acad Dermatol. 2001; 44: S65–72PubMedCrossRefGoogle Scholar
  78. 78.
    Van Leent EJM, Graeber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998; 134: 805–9PubMedCrossRefGoogle Scholar
  79. 79.
    Luger T, Van Leent EJM, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001; 144: 788–94PubMedCrossRefGoogle Scholar
  80. 80.
    Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002; 138: 495–504CrossRefGoogle Scholar
  81. 81.
    Ho V, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003; 142: 155–62PubMedCrossRefGoogle Scholar
  82. 82.
    Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002; 205: 271–7PubMedCrossRefGoogle Scholar
  83. 83.
    Breuer K, Brautigam M, Kapp M, et al. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology. 2004; 209 (4): 314–20PubMedCrossRefGoogle Scholar
  84. 84.
    Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004; 51 (4): 515–25PubMedCrossRefGoogle Scholar
  85. 85.
    Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004; 150 (3): 554–62PubMedCrossRefGoogle Scholar
  86. 86.
    Breuer K, Werfel T, Kapp A. Pimecrolimus for the treatment of atopic dermatitis. Therapy. In pressGoogle Scholar
  87. 87.
    Reitamo S, Wollenberg A, Schoepf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermalot. 2000; 136: 999–1006CrossRefGoogle Scholar
  88. 88.
    Bonifazi E, Garofalo L, Pisani V, et al. Role of some infectious agents in atopic dermatitis. Acta Dermatol Venereol Stockh. 1985; 114: 98–100Google Scholar
  89. 89.
    Fleischer AB, Ling M, Eichenfield L, et al.et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol. 2002; 47: 562–70PubMedCrossRefGoogle Scholar
  90. 90.
    Blankenship JR, Steinbach WJ, Perfect JR, et al. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Invest Drugs. 2003; 4: 192–9Google Scholar
  91. 91.
    Protopic prescribing information. Deerfield (IL): Fujisawa, 2002Google Scholar
  92. 92.
    Rico MJ, Naylor M, Elmets CA, et al. Treatment with tacrolimus ointment is not associated with an increase in non-melanoma skin cancer [abstract]. J Fur Acad Dermatol Venerol. 2003; 17 Suppl. 1: 53Google Scholar
  93. 93.
    Oikarinen A, Haapasaari KM, Smitten M, et al. The molecular basis of glucocorti-coid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vitro. Br J Dermatol. 1998; 139: 1106–10PubMedCrossRefGoogle Scholar
  94. 94.
    Hisatomi A, Mitamura T, Kimura M, et al. Comparison of FK506 (tacrolimus) and glucocorticoid ointment on dermal hogeneity in rats. J Toxicol Pathol. 1997; 10: 97–102CrossRefGoogle Scholar
  95. 95.
    Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998; 111: 396–8PubMedCrossRefGoogle Scholar
  96. 96.
    Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 1997; 137: 568–76PubMedCrossRefGoogle Scholar
  97. 97.
    Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001; 144: 507–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Kristine Breuer
    • 1
  • Thomas Werfel
    • 1
  • Alexander Kapp
    • 1
  1. 1.Department of Dermatology and AllergologyHannover Medical UniversityHannoverGermany

Personalised recommendations